Partner Article

Optibiotix signs deal with international food ingredient company

OptiBiotix, one of the world leader’s in the development of human microbiome modulators, has signed a manufacturing and supply agreement with SACCO to market its cholesterol reducing probiotic strain LP LDL® to the more than 2500 food, beverage, consumer healthcare and pharmaceutical companies it serves across Europe.

LP LDL® is a revolutionary ingredient which has been proven in double blind placebo controlled trials1 to both lower cholesterol and blood pressure and when combined with a prebiotic can increase the production and function of a specific bacterium in the microbiome - a world first.

LP LDL® will be supplied as a raw ingredient by SACCO under a profit sharing agreement which allows it to be added to many types of food or beverage as well as incorporated into pharmaceuticals or supplements. In addition to profit sharing supply of ingredients by Sacco OptiBiotix will negotiate separate licence agreements with each partner gaining royalties on the higher value generic and branded consumer healthcare and pharmaceutical products.

SACCO is one of Europe’s leading probiotic manufacturers and supplies raw materials including some of the world’s best-selling probiotic strains. The agreement grants SACCO an exclusive licence to manufacture, market and supply ingredients in Europe.

OptiBiotix is in discussions with other partners in the US, Asian and other international markets.

Microbiologist Stephen O’Hara CEO of OptiBiotix commented, “We are delighted to partner with SACCO in Europe. This furthers our strategy to build a network of distributors around the world to service the food, beverage and healthcare industries. The development of LP-LDL has caused a great deal of interest and we are in discussion with several other parties to further our geographic reach.”

Looking to the future Stephen said, “I believe we are fast approaching the next stage in the development of the microbiome in healthcare, where scientists will have the ability to precision engineer components of the microbiome to prevent, manage, and treat many of today’s chronic lifestyle diseases. OptiBiotix will continue to be at the forefront of global microbiome research and the development of new products.”

1The trials were carried out by Professor Gibson, Professor of Food Microbiology, Head of Food Microbial Sciences at University of Reading and Professor Bob Rastall, Professor of Food Biotechnology and Head of Food and Nutritional Sciences at University of Reading.

The human microbiome

The human digestive tract contains a complex and diverse ecosystem of trillions of bacteria. Recently, advances in molecular and analytical techniques (metagenomics, metabolomics) have permitted identification and quantitation of species and strains of bacteria that inhabit the gastrointestinal tract, their metabolic activity, and interactions with the human host. These studies have provided greater insight into the role of gut and their metabolites in health and disease.

NIH https://commonfund.nih.gov/hmp/index

Web MD http://www.webmd.com/digestive-disorders/what-your-gut-bacteria-say-your-health#1

About OptiBiotix

OptiBiotix was formed in March 2012 by microbiologist Stephen O’Hara to develop compounds which modify the human microbiome – the collective genome of the microbes in the body – to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

http://www.optibiotix.com/

OptiBiotix, one of the world leader’s in the development of human microbiome modulators, has signed a manufacturing and supply agreement with SACCO to market its cholesterol reducing probiotic strain LP LDL® to the more than 2500 food, beverage, consumer healthcare and pharmaceutical companies it serves across Europe.

LP LDL® is a revolutionary ingredient which has been proven in double blind placebo controlled trials1 to both lower cholesterol and blood pressure and when combined with a prebiotic can increase the production and function of a specific bacterium in the microbiome - a world first.

LP LDL® will be supplied as a raw ingredient by SACCO under a profit sharing agreement which allows it to be added to many types of food or beverage as well as incorporated into pharmaceuticals or supplements. In addition to profit sharing supply of ingredients by Sacco OptiBiotix will negotiate separate licence agreements with each partner gaining royalties on the higher value generic and branded consumer healthcare and pharmaceutical products.

SACCO is one of Europe’s leading probiotic manufacturers and supplies raw materials including some of the world’s best-selling probiotic strains. The agreement grants SACCO an exclusive licence to manufacture, market and supply ingredients in Europe.

OptiBiotix is in discussions with other partners in the US, Asian and other international markets.

Microbiologist Stephen O’Hara CEO of OptiBiotix commented, “We are delighted to partner with SACCO in Europe. This furthers our strategy to build a network of distributors around the world to service the food, beverage and healthcare industries. The development of LP-LDL has caused a great deal of interest and we are in discussion with several other parties to further our geographic reach.”

Looking to the future Stephen said, “I believe we are fast approaching the next stage in the development of the microbiome in healthcare, where scientists will have the ability to precision engineer components of the microbiome to prevent, manage, and treat many of today’s chronic lifestyle diseases. OptiBiotix will continue to be at the forefront of global microbiome research and the development of new products.”

1The trials were carried out by Professor Gibson, Professor of Food Microbiology, Head of Food Microbial Sciences at University of Reading and Professor Bob Rastall, Professor of Food Biotechnology and Head of Food and Nutritional Sciences at University of Reading.

The human microbiome

The human digestive tract contains a complex and diverse ecosystem of trillions of bacteria. Recently, advances in molecular and analytical techniques (metagenomics, metabolomics) have permitted identification and quantitation of species and strains of bacteria that inhabit the gastrointestinal tract, their metabolic activity, and interactions with the human host. These studies have provided greater insight into the role of gut and their metabolites in health and disease.

NIH https://commonfund.nih.gov/hmp/index

Web MD http://www.webmd.com/digestive-disorders/what-your-gut-bacteria-say-your-health#1

About OptiBiotix

OptiBiotix was formed in March 2012 by microbiologist Stephen O’Hara to develop compounds which modify the human microbiome – the collective genome of the microbes in the body – to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

http://www.optibiotix.com/

This was posted in Bdaily's Members' News section by VPR .